Trimodality therapy for advanced gallbladder cancer

Aaron R. Sasson, John P. Hoffman, Eric Ross, Neal J. Meropol, Christine E. Szarka, Gary Freedman, Wayne Pinover, James F. Pingpank, Burton L. Eisenberg

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


We conducted a retrospective review of all patients who underwent surgical extirpation for stage III, stage IV, or recurrent carcinoma of the gallbladder. Between 1991 and 1999 ten patients underwent surgical resection for advanced gallbladder cancer. All patients received adjuvant therapy either pre- or postoperatively. Radiotherapy was used in all patients and chemotherapy in 90 per cent of patients. Two patients subsequently underwent resection for locally recurrent disease. An additional patient with stage II disease initially was also treated surgically for a local recurrence. Surgical management involved cholecystectomy and resection of various amounts of liver surrounding the gallbladder bed and regional lymphadenectomy. Contiguously involved structures were resected en bloc. Resection of recurrent disease included excision of all gross tumor. The median overall survival excluding the one 30-day mortality was 53.6 months (range 8-73 months). Four patients have survived 4 or more years, and currently four patients are alive and disease free at 73, 49, 33, and 8 months. Median disease-free interval after each resection of recurrent disease was 13.8 months (range 4-28 months). We conclude that trimodality therapy in selected patients with stage III, IV, or recurrent carcinoma of the gallbladder is possible and may result in prolonged survival.

Original languageEnglish (US)
Pages (from-to)277-283
Number of pages7
JournalAmerican Surgeon
Issue number3
StatePublished - 2001

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Trimodality therapy for advanced gallbladder cancer'. Together they form a unique fingerprint.

Cite this